{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=14%3A10+Regimen", "query": { "intervention": "14:10 Regimen" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 194, "total_pages": 20, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=14%3A10+Regimen&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-22T09:39:19.573Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02004262", "title": "Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "2nd-line, 3rd-line and Greater Metastatic Pancreatic Cancer" ], "interventions": [ { "name": "GVAX Pancreas Vaccine", "type": "BIOLOGICAL" }, { "name": "CRS-207", "type": "BIOLOGICAL" }, { "name": "Chemotherapy", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Aduro Biotech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 303, "start_date": "2014-02-05", "completion_date": "2016-08-23", "has_results": true, "last_update_posted_date": "2018-06-04", "last_synced_at": "2026-09-22T09:39:19.573Z", "location_count": 20, "location_summary": "Scottsdale, Arizona • La Jolla, California • San Francisco, California + 16 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02004262" }, { "nct_id": "NCT04827979", "title": "Daratumumab and Belatacept for Desensitization", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Highly Sensitized Prospective Kidney Transplant Recipients" ], "interventions": [ { "name": "daratumumab", "type": "BIOLOGICAL" }, { "name": "belatacept", "type": "BIOLOGICAL" }, { "name": "Bone marrow aspiration", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 19, "start_date": "2021-11-01", "completion_date": "2026-04-02", "has_results": false, "last_update_posted_date": "2026-07-24", "last_synced_at": "2026-09-22T09:39:19.573Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04827979" }, { "nct_id": "NCT00408408", "title": "Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "bevacizumab", "type": "BIOLOGICAL" }, { "name": "capecitabine", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "docetaxel", "type": "DRUG" }, { "name": "doxorubicin hydrochloride (Adriamycin)", "type": "DRUG" }, { "name": "gemcitabine hydrochloride", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "NSABP Foundation Inc", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "FEMALE", "summary": "18 Years to 120 Years · Female only" }, "enrollment_count": 1206, "start_date": "2006-11", "completion_date": "2018-03", "has_results": true, "last_update_posted_date": "2017-09-18", "last_synced_at": "2026-09-22T09:39:19.573Z", "location_count": 432, "location_summary": "Little Rock, Arkansas • Castro Valley, California • Fremont, California + 287 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Castro Valley", "state": "California" }, { "city": "Castro Valley", "state": "California" }, { "city": "Castro Valley", "state": "California" }, { "city": "Fremont", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00408408" }, { "nct_id": "NCT00957918", "title": "Study of NP002 in Subjects With Idiopathic Parkinson's Disease to Treat Dyskinesias Due to Levodopa Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Parkinson's Disease" ], "interventions": [ { "name": "nicotine", "type": "DRUG" }, { "name": "placebo comparator", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Neuraltus Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": "83 Years", "sex": "ALL", "summary": "30 Years to 83 Years" }, "enrollment_count": 65, "start_date": "2009-10", "completion_date": "2010-09", "has_results": false, "last_update_posted_date": "2011-10-05", "last_synced_at": "2026-09-22T09:39:19.573Z", "location_count": 12, "location_summary": "Phoenix, Arizona • Los Angelis, California • Oxnard, California + 9 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angelis", "state": "California" }, { "city": "Oxnard", "state": "California" }, { "city": "Englewood", "state": "Colorado" }, { "city": "Boca Raton", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00957918" }, { "nct_id": "NCT00961753", "title": "Safety/Efficacy Study of Optimizing Ibuprofen Dosing to Achieve Higher PDA Closure Rates", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Patent Ductus Arteriosus" ], "interventions": [ { "name": "optimized ibuprofen", "type": "DRUG" }, { "name": "Standard Ibuprofen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "OSF Healthcare System", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Day", "maximum_age": "29 Days", "sex": "ALL", "summary": "1 Day to 29 Days" }, "enrollment_count": 10, "start_date": "2009-08", "completion_date": "2010-10", "has_results": false, "last_update_posted_date": "2014-01-28", "last_synced_at": "2026-09-22T09:39:19.573Z", "location_count": 1, "location_summary": "Peoria, Illinois", "locations": [ { "city": "Peoria", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00961753" }, { "nct_id": "NCT03029143", "title": "Vedolizumab Intravenous (IV) Dose Optimization in Ulcerative Colitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Colitis, Ulcerative" ], "interventions": [ { "name": "Vedolizumab IV", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 278, "start_date": "2017-03-29", "completion_date": "2020-10-16", "has_results": true, "last_update_posted_date": "2023-07-28", "last_synced_at": "2026-09-22T09:39:19.573Z", "location_count": 44, "location_summary": "Tucson, Arizona • Little Rock, Arkansas • San Pablo, California + 40 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "San Pablo", "state": "California" }, { "city": "San Pablo", "state": "California" }, { "city": "Bridgeport", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT03029143" }, { "nct_id": "NCT02455076", "title": "Exenatide Inpatient Trial: A Randomized Controlled Pilot Trial on the Safety and Efficacy of Exenatide (Byetta®) Therapy for the Inpatient Management of Patients With Type 2 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Type 2 Diabetes" ], "interventions": [ { "name": "Exenatide", "type": "DRUG" }, { "name": "Glargine", "type": "DRUG" }, { "name": "Rapid-acting insulin analogs", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 150, "start_date": "2015-09", "completion_date": "2018-03", "has_results": true, "last_update_posted_date": "2019-06-20", "last_synced_at": "2026-09-22T09:39:19.573Z", "location_count": 2, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02455076" }, { "nct_id": "NCT00002944", "title": "Combination Chemotherapy in Treating Children With Progressive Brain Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Brain Tumors", "Central Nervous System Tumors" ], "interventions": [ { "name": "carboplatin", "type": "DRUG" }, { "name": "lomustine", "type": "DRUG" }, { "name": "procarbazine hydrochloride", "type": "DRUG" }, { "name": "thioguanine", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "9 Years", "sex": "ALL", "summary": "Up to 9 Years" }, "enrollment_count": 428, "start_date": "1997-04", "completion_date": "2012-04", "has_results": false, "last_update_posted_date": "2013-09-09", "last_synced_at": "2026-09-22T09:39:19.573Z", "location_count": 179, "location_summary": "Mobile, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 141 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Downey", "state": "California" }, { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002944" }, { "nct_id": "NCT00311311", "title": "Study Comparing Effect On Carotid Atherosclerosis Following Conversion From Tacrolimus To Sirolimus Post-Transplant In Kidney Transplant Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Atherosclerosis", "Kidney Failure" ], "interventions": [ { "name": "tacrolimus", "type": "DRUG" }, { "name": "mycophenolate mofetil", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "sirolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "35 Years", "maximum_age": null, "sex": "ALL", "summary": "35 Years and older" }, "enrollment_count": 72, "start_date": "2006-04", "completion_date": "2012-01", "has_results": true, "last_update_posted_date": "2013-09-23", "last_synced_at": "2026-09-22T09:39:19.573Z", "location_count": 1, "location_summary": "Rochester, New York", "locations": [ { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00311311" }, { "nct_id": "NCT06257706", "title": "VECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Moderately to Severely Active Crohn's Disease", "Crohn Disease", "Disease Crohn" ], "interventions": [ { "name": "Vedolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Alimentiv Inc.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 304, "start_date": "2024-08-07", "completion_date": "2029-02-06", "has_results": false, "last_update_posted_date": "2026-01-15", "last_synced_at": "2026-09-22T09:39:19.573Z", "location_count": 3, "location_summary": "Los Angeles, California • Charleston, South Carolina • Houston, Texas", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Charleston", "state": "South Carolina" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06257706" } ] }